Product image of Neupro (Rotigotine) supplied by GNH India

Neupro

Active Ingredient:
Rotigotine
Origin:
EU

Neupro (Rotigotine)

Rotigotine, the active ingredient in Neupro, is a dopamine agonist presented as a 2 mg/24 h, 4 mg/24 h, 6 mg/24 h or 8 mg/24 h transdermal patch for transdermal use. It provides continuous dopaminergic stimulation over a 24‑hour period, improving symptom control and patient convenience. It is prescribed to manage motor symptoms in Parkinson's disease and to relieve uncomfortable sensations in Restless Legs Syndrome in adult patients.

GNH India supplies Neupro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is distributed under a prescription‑only status.

Manufacturer / TM Owner

Ucb Pharma S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Rotigotine is a non‑ergot dopamine agonist used in movement‑disorder therapy.

  • Parkinson's disease: improves motor function and reduces “off” periods in adults with idiopathic Parkinson's disease.
  • Restless Legs Syndrome: lessens uncomfortable leg sensations and decreases the urge to move in adults with moderate to severe RLS.

How It Works

  • Rotigotine acts as a non‑ergot dopamine receptor agonist, binding to D1, D2 and D3 receptors in the central nervous system. By stimulating these receptors, it enhances dopaminergic neurotransmission, which helps to normalize motor control pathways that are deficient in Parkinson's disease and modulates sensory pathways implicated in Restless Legs Syndrome.

Side Effects

Rotigotine may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Application site reaction: erythema, itching or irritation at the patch site.
  • Dizziness: transient light‑headedness, especially on standing.
  • Somnolence: increased sleepiness or fatigue.
  • Dry mouth: reduced salivation leading to discomfort.
  • Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects

  • Hallucinations: visual or auditory disturbances, more common at higher doses.
  • Impulse control disorders: compulsive gambling, shopping or hypersexuality.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Orthostatic hypotension: marked blood pressure drop upon standing.
  • Depression or suicidal ideation: worsening mood or emergence of suicidal thoughts.
  • Severe allergic reaction: anaphylaxis or angioedema.

Precautions & Warnings

When prescribing Rotigotine, clinicians should consider several safety precautions to minimize risk.

  • Monitor for hallucinations: visual or auditory hallucinations may appear, especially at higher doses.
  • Assess impulse control: patients may develop compulsive behaviors such as gambling or hypersexuality.
  • Check cardiovascular status: orthostatic hypotension and hypertension have been reported.
  • Evaluate psychiatric history: depression or suicidal thoughts may worsen.
  • Store at below 25°C: keep in the original pouch, protect from moisture and light.

Avoid Interactions

Rotigotine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • MAO‑B inhibitors (e.g., selegiline, rasagiline): may cause hypertensive crisis.
  • Dopamine antagonists (e.g., typical antipsychotics): reduce therapeutic effect of rotigotine.

Moderate Interactions (Monitor Closely)

  • CYP1A2 inhibitors (e.g., fluvoxamine): may increase rotigotine plasma levels.
  • Antihypertensive agents: additive blood‑pressure‑lowering effect.
  • SSRIs or SNRIs: may raise risk of impulse‑control disorders.

Frequently Asked Questions

Neupro is a transdermal patch that delivers rotigotine, a dopamine agonist, to treat motor symptoms in Parkinson's disease and to relieve the uncomfortable sensations and urge to move that characterize Restless Legs Syndrome in adult patients.

Rotigotine stimulates dopamine D1, D2 and D3 receptors in the brain, providing continuous dopaminergic activation. This compensates for the dopamine deficiency seen in Parkinson's disease and modulates sensory pathways involved in Restless Legs Syndrome, helping to improve motor control and reduce leg discomfort.

The prescribed dose is individualized by the treating physician. Neupro patches are available in 2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h strengths, and the clinician selects the appropriate strength and titration schedule based on the patient’s response and tolerability.

Safety data for rotigotine in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies the potential risk to the fetus or infant, and it is generally avoided unless no suitable alternative therapy is available.

To request Neupro, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Neupro offers continuous 24‑hour drug delivery via a skin patch, which can improve adherence compared with oral agents such as pramipexole or ropinirole that require multiple daily doses. However, skin‑related reactions are more common with the patch, while oral agents may have fewer local site issues.

Neupro patches should be stored at temperatures below 25 °C, in the original pouch, protected from moisture and light. Keep the product out of reach of children and avoid exposing it to excessive heat or direct sunlight.

Neupro is applied to clean, dry, hair‑free skin on the upper arm, thigh, abdomen or back. The patch is worn for 24 hours and then replaced with a new patch of the same strength. Rotation of the application site is recommended to reduce skin irritation.

Serious risks include hallucinations, impulse‑control disorders (such as compulsive gambling or hypersexuality), severe skin reactions like Stevens‑Johnson syndrome, orthostatic hypotension, and worsening depression or emergence of suicidal thoughts. Patients should be monitored closely for these events.

Neupro is contraindicated in individuals with known hypersensitivity to rotigotine or any patch components, in patients with severe hepatic impairment, and in those with a history of severe skin reactions to transdermal products. Caution is also advised for patients with uncontrolled psychiatric disorders.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Rotigotine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT